Apnimed presents Phase 3 AD109 obstructive sleep apnea data at CHEST 2026
Apnimed flagged five CHEST 2026 presentations tied to its Phase 3 program for investigational oral OSA drug AD109. Data will be presented Oct. 20-21 in Phoenix, including late-breaking analyses in post-menopausal women and blood-pressure response markers. Another Phase 3 presentation will cover patient-reported outcome